Logo image of KME.MI

KME GROUP SPA (KME.MI) Stock Fundamental Analysis

BIT:KME - Euronext Milan - IT0004552359 - Common Stock - Currency: EUR

0.904  -0.03 (-2.8%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to KME. KME was compared to 40 industry peers in the Metals & Mining industry. KME may be in some trouble as it scores bad on both profitability and health. KME has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

KME had negative earnings in the past year.
KME had a positive operating cash flow in the past year.
In multiple years KME reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: KME reported negative operating cash flow in multiple years.
KME.MI Yearly Net Income VS EBIT VS OCF VS FCFKME.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M 150M 200M

1.2 Ratios

Looking at the Return On Assets, with a value of -4.45%, KME is doing worse than 86.49% of the companies in the same industry.
Looking at the Return On Equity, with a value of -34.68%, KME is doing worse than 97.30% of the companies in the same industry.
Industry RankSector Rank
ROA -4.45%
ROE -34.68%
ROIC N/A
ROA(3y)3.02%
ROA(5y)1.79%
ROE(3y)1.63%
ROE(5y)0.95%
ROIC(3y)N/A
ROIC(5y)N/A
KME.MI Yearly ROA, ROE, ROICKME.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 5 -5 10 -10

1.3 Margins

In the last couple of years the Operating Margin of KME has declined.
Looking at the Gross Margin, with a value of 30.17%, KME is in line with its industry, outperforming 51.35% of the companies in the same industry.
KME does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 30.17%
OM growth 3Y-61.86%
OM growth 5Y-50.11%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KME.MI Yearly Profit, Operating, Gross MarginsKME.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 2K 4K 6K

More info and screens

2

2. Health

2.1 Basic Checks

KME does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for KME has been reduced compared to 1 year ago.
The number of shares outstanding for KME has been reduced compared to 5 years ago.
The debt/assets ratio for KME is higher compared to a year ago.
KME.MI Yearly Shares OutstandingKME.MI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M
KME.MI Yearly Total Debt VS Total AssetsKME.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B 2B

2.2 Solvency

KME has an Altman-Z score of 0.75. This is a bad value and indicates that KME is not financially healthy and even has some risk of bankruptcy.
KME has a worse Altman-Z score (0.75) than 86.49% of its industry peers.
KME has a debt to FCF ratio of 9.84. This is a negative value and a sign of low solvency as KME would need 9.84 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 9.84, KME is doing good in the industry, outperforming 67.57% of the companies in the same industry.
KME has a Debt/Equity ratio of 1.25. This is a high value indicating a heavy dependency on external financing.
KME has a Debt to Equity ratio of 1.25. This is amonst the worse of the industry: KME underperforms 86.49% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.25
Debt/FCF 9.84
Altman-Z 0.75
ROIC/WACCN/A
WACC8.87%
KME.MI Yearly LT Debt VS Equity VS FCFKME.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M

2.3 Liquidity

KME has a Current Ratio of 0.72. This is a bad value and indicates that KME is not financially healthy enough and could expect problems in meeting its short term obligations.
KME's Current ratio of 0.72 is on the low side compared to the rest of the industry. KME is outperformed by 94.59% of its industry peers.
A Quick Ratio of 0.30 indicates that KME may have some problems paying its short term obligations.
With a Quick ratio value of 0.30, KME is not doing good in the industry: 97.30% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.72
Quick Ratio 0.3
KME.MI Yearly Current Assets VS Current LiabilitesKME.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

More info and screens

2

3. Growth

3.1 Past

KME shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -642.67%.
KME shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -26.34%.
KME shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 120.96% yearly.
EPS 1Y (TTM)-642.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-328.94%
Revenue 1Y (TTM)-26.34%
Revenue growth 3Y424.94%
Revenue growth 5Y120.96%
Sales Q2Q%-26.61%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KME.MI Yearly Revenue VS EstimatesKME.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B
KME.MI Yearly EPS VS EstimatesKME.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for KME. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KME.MI Price Earnings VS Forward Price EarningsKME.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

KME's Enterprise Value to EBITDA ratio is rather expensive when compared to the industry. KME is more expensive than 81.08% of the companies in the same industry.
KME's Price/Free Cash Flow ratio is rather cheap when compared to the industry. KME is cheaper than 94.59% of the companies in the same industry.
Industry RankSector Rank
P/FCF 4.35
EV/EBITDA 18.89
KME.MI Per share dataKME.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

KME does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KME GROUP SPA

BIT:KME (3/3/2025, 7:00:00 PM)

0.904

-0.03 (-2.8%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryMetals & Mining
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners0.07%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap257.13M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.01
Dividend Growth(5Y)-14.86%
DP-0.04%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.16
P/FCF 4.35
P/OCF 2.86
P/B 1.02
P/tB N/A
EV/EBITDA 18.89
EPS(TTM)-0.97
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.21
FCFY22.97%
OCF(TTM)0.32
OCFY34.93%
SpS5.6
BVpS0.89
TBVpS-0.67
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.45%
ROE -34.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 30.17%
FCFM 3.71%
ROA(3y)3.02%
ROA(5y)1.79%
ROE(3y)1.63%
ROE(5y)0.95%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-61.86%
OM growth 5Y-50.11%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.81
Health
Industry RankSector Rank
Debt/Equity 1.25
Debt/FCF 9.84
Debt/EBITDA 8.21
Cap/Depr 53.79%
Cap/Sales 1.93%
Interest Coverage N/A
Cash Conversion 233.01%
Profit Quality N/A
Current Ratio 0.72
Quick Ratio 0.3
Altman-Z 0.75
F-Score5
WACC8.87%
ROIC/WACCN/A
Cap/Depr(3y)49.67%
Cap/Depr(5y)76.47%
Cap/Sales(3y)14.27%
Cap/Sales(5y)10.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-642.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-328.94%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-26.34%
Revenue growth 3Y424.94%
Revenue growth 5Y120.96%
Sales Q2Q%-26.61%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-126.42%
EBIT growth 3Y100.22%
EBIT growth 5Y10.24%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-61.04%
FCF growth 3YN/A
FCF growth 5Y18.49%
OCF growth 1Y-43.3%
OCF growth 3YN/A
OCF growth 5Y27.95%